The ipsogen BCR-ABL1 mbcr Kit is a ready-to-use kit for the detection of BCR-ABL mbcr p190 e1a2 fusion gene transcripts using real-time PCR. The kit is based on the amplification and detection of specific BCR-ABL p190 e1a2 transcripts, relative to ABL control gene expression, in total RNA extracted from bone marrow or peripheral blood samples of Ph-positive acute lymphoblastic leukemia (ALL) patients previously diagnosed with a BCR-ABL mbcr fusion gene event (see figures BCR-ABL mbcr fusion gene transcript and ABL control gene transcript). The kit provides high levels of specificity, sensitivity, and reproducibility. The ipsogen BCR-ABL1 mbcr Kit provides 5 standard dilutions for BCR-ABL mbcr and 3 standard dilutions for ABL. Use of the standards enables accurate quantification of transcripts. The technology used for quantification of BCR-ABL mbcr has been standardized according to Europe Against Cancer (EAC) recommendations and the ipsogen BCR-ABL1 mbcr Kit uses this validated technology to calibrate results.

Procedure

The first step is reverse transcription of total RNA in a sample into cDNA. The second step is the amplification of cDNA by real-time PCR. Using the ipsogen BCR-ABL1 mbcr Kit allows detection and quantification of BCR-ABL mbcr p190 e1a2 and ABL transcripts. Simply start the reaction using the optimized protocols described in the kit handbook.